SCHEMBL3609468

SCHEMBL3609468

CCOC(=O)/C(C)=C/c1ccc(C)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.58
MEN1 O00255 8/20 0.58
KMT2A Q03164 8/20 0.58
LMNA P02545 2/20 0.58
NPSR1 Q6W5P4 2/20 0.58
MAPK1 P28482 2/20 0.58
S1PR4 O95977 1/20 0.58
S1PR1 P21453 1/20 0.58
CYP1A2 P05177 1/20 0.54
CYP2C9 P11712 1/20 0.54
CYP2C19 P33261 1/20 0.54
DHODH Q02127 1/20 0.49
SMN1; SMN2 Q16637 3/20 0.46
HTT P42858 2/20 0.46
GAA P10253 1/20 0.46
ALDH1A1 P00352 5/20 0.46
KDM4E B2RXH2 4/20 0.46
HSP90AA1 P07900 2/20 0.45
HPGD P15428 1/20 0.45
NR1H4 Q96RI1 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3609471 1.00 MAPT (0.58) MAPTMEN1KMT2ALMNANPSR1
SCHEMBL10564181 0.88 MAPT (0.57) MAPTMEN1KMT2ALMNANPSR1
SCHEMBL321922 0.88 MAPT (0.57) MAPTMEN1KMT2ALMNANPSR1
SCHEMBL14358911 0.88 MAPT (0.57) MAPTMEN1KMT2ALMNANPSR1
SCHEMBL7651650 0.88 KMT2A (0.76) MAPTMEN1KMT2ALMNANPSR1
SCHEMBL7030290 0.88 KMT2A (0.76) MAPTMEN1KMT2ALMNANPSR1
SCHEMBL10885404 0.88 MAPT (0.57) MAPTMEN1KMT2ALMNANPSR1
SCHEMBL5617201 0.88 KMT2A (0.57) MAPTMEN1KMT2ALMNANPSR1
SCHEMBL12035802 0.88 KMT2A (0.57) MAPTMEN1KMT2ALMNANPSR1
SCHEMBL321923 0.88 MAPT (0.57) MAPTMEN1KMT2ALMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100240743-A1 CANNABINOID RECEPTOR MODULATOR TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-23 US disclosed
US-7507841-B2 Carbamoylamino-substituted 2,3-dihydro-benzofurans, indoles and benzothiophenes, e.g., (+)-N-((3R)-3-(4-isopropylphenyl)-4,6,7-trimethyl-2,3-dihydro-1-benzofuran-5-yl)-3,3-dimethylbutanamide; cerebrovascular disorders TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-03-24 US disclosed
US-20090023800-A1 Cannabinoid receptor modulator TAKEDA PHARMACEUTICAL COMPANY LIMITED 2009-01-22 US disclosed
EP-1323716-B1 PROMOTERS FOR THE PROLIFERATION AND DIFFERENTIATION OF STEM CELLS AND/OR NEURON PRECURSOR CELLS TAKEDA PHARMACEUTICAL (JP) 2009-01-14 EP disclosed
US-20090012081-A1 Agents for promoting the proliferation or differentiation of stem cells or neural progenitor cells TAKEDA PHARMACEUTICAL COMPANY LTD. (JP) 2009-01-08 US disclosed
US-7456162-B2 Benzofuran derivatives, their production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-11-25 US disclosed
EP-1346988-B1 PROCESS FOR PREPARING OPTICALLY ACTIVE 2,3-DIHYDRO- BENZOFURAN COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2008-11-12 EP disclosed
US-7420070-B2 Process for preparing optically active 2,3-dihydrobenzofuran compounds TAKODA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-09-02 US disclosed
US-20080167347-A1 Antidiabetic, antiproliferative, anticancer agents; benzanilide derivatives SHIONGI & CO., LTD. (JP) 2008-07-10 US disclosed
US-20080167347-A1 Antidiabetic, antiproliferative, anticancer agents; benzanilide derivatives SHIONGI & CO., LTD. (JP) 2008-07-10 US disclosed
US-20050171184-A1 Process for preparing optically active 2,3-dihydrobenzofuran compounds AOKI ISAO (JP) 2005-08-04 US disclosed
US-6878831-B2 Process for preparing optically active 2,3-dihydrobenzofuran compounds TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2005-04-12 US disclosed
US-20040077712-A1 Process for preparing optically active 2,3-dihydrobenzofuran compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-04-22 US disclosed
EP-1136477-B1 BENZOFURAN DERIVATIVES, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2004-03-10 EP disclosed
US-20040034049-A1 Promoters for the proliferation and differentiation of stem cells and/or neuron precursor cells TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-02-19 US disclosed
EP-1346988-A1 PROCESS FOR PREPARING OPTICALLY ACTIVE 2,3-DIHYDRO- BENZOFURAN COMPOUNDS Takeda Chemical Industries, Ltd. (JP) 2003-09-24 EP disclosed
EP-1323716-A1 PROMOTERS FOR THE PROLIFERATION AND DIFFERENTIATION OF STEM CELLS AND/OR NEURON PRECURSOR CELLS Takeda Chemical Industries, Ltd. (JP) 2003-07-02 EP disclosed
US-6479536-B1 Benzofuran derivatives, process for the preparation of the same and uses thereof TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2002-11-12 US disclosed
US-20020160996-A1 Benzofuran derivatives, their production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2002-10-31 US disclosed
EP-1136477-A1 BENZOFURAN DERIVATIVES, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF Takeda Chemical Industries, Ltd. (JP) 2001-09-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171184-A1 Process for preparing optically active 2,3-dihydrobenzofuran compounds ALDH1A2, DHPS, DHODH MAPT 465/4885MEN1 1951/4885KMT2A 3056/4885
US-20090012081-A1 Agents for promoting the proliferation or differentiation of stem cells or neural progenitor cells NES, MKI67, CCNO MAPT 4127/4885MEN1 2906/4885KMT2A 1061/4885
US-20100240743-A1 CANNABINOID RECEPTOR MODULATOR CNR1, CNR2, GPR18 MAPT 4392/4885MEN1 3532/4885KMT2A 1061/4885
US-20040077712-A1 Process for preparing optically active 2,3-dihydrobenzofuran compounds ALDH1A2, PARK7, DHPS MAPT 392/4885MEN1 2199/4885KMT2A 3019/4885
US-20080167347-A1 Antidiabetic, antiproliferative, anticancer agents; benzanilide derivatives CCNY, HDGF, GLI1 MAPT 4741/4885MEN1 1970/4885KMT2A 2466/4885
US-20090023800-A1 Cannabinoid receptor modulator CNR1, CNR2, GPR18 MAPT 4392/4885MEN1 3532/4885KMT2A 1061/4885
US-20040034049-A1 Promoters for the proliferation and differentiation of stem cells and/or neuron precursor cells NES, HAT1, PROX1 MAPT 4443/4885MEN1 3718/4885KMT2A 451/4885
US-20020160996-A1 Benzofuran derivatives, their production and use PARK7, WDR1, WHR1 MAPT 813/4885MEN1 3777/4885KMT2A 2045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.